Henri Termeer served for nearly 30 years as the chairman, president and CEO of Genzyme, until Sanofi acquired the company in 2011 in a transaction valued at more than $20 billion. Under his leadership, Genzyme grew from a modest entrepreneurial venture to one of the world’s leading biotechnology companies. Earlier in his career, Henri was the executive vice president of Baxter Travenol Laboratories (now Baxter International). Henri has an MBA from the Darden Business School at the University of Virginia and a degree in economics from Erasmus University.
A leader in the biotechnology industry and health care field, Henri is chairman emeritus of the New England Healthcare Institute and currently serves on the boards of directors for several organizations, including Massachusetts General Hospital, Partners HealthCare, the Massachusetts Institute of Technology, the Biotechnology Industry Organization (BIO) and the Life Sciences Foundation (LSF). He is also a board member of the following companies: Abiomed Inc., Aveo Pharmaceuticals, Moderna Therapeutics, ProQR Therapeutics and Verastem Inc. Henri has earned numerous awards for his contributions to the health care field and global business, including Frost and Sullivan’s Pharmaceuticals and Biotechnology’s Lifetime Achievement Award in 2009 and Ernst Young’s Master Entrepreneur Award in 2007.